Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)

Study identifier:D3250R00109

ClinicalTrials.gov identifier:NCT05734339

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan

Medical condition

asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

43

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 19 Jan 2023
Estimated Primary Completion Date: 31 Jul 2024
Estimated Study Completion Date: 31 Jul 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria